This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Colorado Kids Get Legal Pot as New York Doctors Can Barely Study It

NEW YORK (TheStreet) -- Doctors are increasingly frustrated about federal marijuana restrictions standing in the way of important research.

"It is troubling that while few barriers exist for parents to give their children marijuana in Colorado, there are significant federal roadblocks preventing doctors from studying it in a rigorous scientific manner," write Orrin Devinsky and Daniel Friedman, physicians at the Comprehensive Epilepsy Center at New York University in The New York Times Wednesday.

The two doctors voiced skepticism about many of the perceived medical benefits of marijuana, and argued that "the recent wave of state legislatures considering and often approving medical marijuana raises significant concerns."

At the same time, however, they state that the government's classification of marijuana as a "schedule 1" drug places severe restrictions on their ability to study the effects of its active ingredients, including the chemical compounds cannabidiol, or CBD, and tetrahydrocannabinol, or THC. 

"While it is possible to study Schedule 1 drugs in a controlled laboratory setting, it is extremely difficult to study these substances in patients. For our study, we keep the CBD in a 1,200-pound safe in a locked room, in a building with an alarm system," the doctors write.

Must Read: Washington Goes to Pot

Similar frustration came through in an article in the latest issue of The New York Review of Books by Harvard Medical School Professor Jerome Groopman, a longtime staff writer for The New Yorker magazine.

While Groopman's article tended more toward information than opinion, he appeared to be more excited than the NYU doctors about the potential medical benefits from marijuana and related drugs. Still, he wrote that as a physician prescribing therapy for patients, he is in "an uncomfortable situation," since even in the 20 states where medical marijuana is legal, it "is regulated like a supplement rather than a drug," with "no standardization of optimal amounts of psychoactive THC and nonpsychoactive CBD."

Proposed legislation, including a bill introduced Wednesday by Steve Cohen (D.-Tenn.) would ease restrictions on medical research involving marijuana.

And Cohen was one of 18 members of Congress who sent a letter to President Obama Wednesday urging him to remove marijuana from the list of schedule I and II drugs. Marijuana is currently a schedule I drug, meaning federal laws regard it as more dangerous than cocaine, which is schedule II. The state and party affiliation of the signers, however, allude to the significant political obstacles to marijuana liberalization at the federal level. Seventeen signers are Democrats and only one, California Rep. Dana Rohrabacher, is a Republican.

Follow @dan_freed

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs